A hypothesis: Edaravone exert cardioprotection partly via modulation of adiponectin

Med Hypotheses. 2012 Aug;79(2):141-2. doi: 10.1016/j.mehy.2012.04.015. Epub 2012 May 8.

Abstract

Edaravone has been recognized as a potential protective agent for cardiovascular diseases. It is well known that edaravone can attenuate oxidative stress and inhibit the production of proinflammatory cytokines such as TNF-α. However, the mechanisms behind the cardioprotection of edaravone are still incompletely understood yet. As a primary adipose-derived protein, adiponectin exhibits protective properties on the heart and blood vessels. Accumulative studies have shown that there exists a reciprocal relationship between adiponectin and TNF-α, i.e., adiponectin negatively regulates TNF-α expression, whereas adiponectin expression is inhibited by TNF-α. So we hypothesize that edaravone plays a role in cardioprotection partly through modulation of adiponectin level by suppression of TNF-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / immunology*
  • Antipyrine / analogs & derivatives*
  • Antipyrine / therapeutic use
  • Cardiotonic Agents / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / immunology*
  • Edaravone
  • Free Radical Scavengers / therapeutic use*
  • Humans
  • Models, Immunological
  • Tumor Necrosis Factor-alpha / immunology*

Substances

  • Adiponectin
  • Cardiotonic Agents
  • Free Radical Scavengers
  • Tumor Necrosis Factor-alpha
  • Edaravone
  • Antipyrine